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ABSTRACT
Thalidomide, lenalidomide and pomalidomide have greatly improved the outcome 
of patients with multiple myeloma. However, their effects on plasma cells, the healthy 
counterpart of myeloma cells, are unknown. Here, we investigated lenalidomide 
effects on normal human plasma cell generation using an in vitro model. Lenalidomide 
inhibited the generation of pre-plasmablasts and early plasma cells, while it 
moderately affected plasmablast production. It also reduced the expression level 
of Ikaros, Aiolos, and IRF4 transcription factors, in plasmablasts and early plasma 
cells. This suggests that their differential sensitivity to lenalidomide is not due to a 
difference in Ikaros or Aiolos degradation. Lenalidomide also inhibited long-lived 
plasma cell generation, but did not impair their long-term survival once generated. 
This last observation is in agreement with the finding that lenalidomide treatment for 
3-18 months did not affect the bone marrow healthy plasma cell count in allografted 
patients with multiple myeloma. Our findings should prompt to investigate whether 
lenalidomide resistance in patients with multiple myeloma could be associated with 
the emergence of malignant plasmablasts or long-lived plasma cells that are less 
sensitive to lenalidomide.
INTRODUCTION
Thalidomide and its immunomodulatory derivatives 
(IMiDs®) lenalidomide and pomalidomide have greatly 
improved the outcome of patients with multiple myeloma 
(MM), a malignant plasma cell (PC) disorder [1–3]. 
IMiDs directly kill multiple myeloma cells (MMCs) 
and also target the tumor environment by stimulating 
T cell function and inhibiting angiogenesis and tumor 
necrosis factor production by monocytes [4]. These 
activities are mediated through IMiD ability to promote 
binding of the Ikaros and Aiolos transcription factors to 
cereblon (CRBN), which forms an E3 ubiquitin ligase 
complex together with damaged DNA binding 1 (DDB1), 
cullin-4A (CUL4A) and regulator of cullins 1 (ROC1) 
[5, 6]. This results in the activation of CRBN E3 ligase 
activity, leading to Ikaros and Aiolos ubiquitination and 
proteasomal degradation [7–9]. As Aiolos and Ikaros 
repress interleukin-2 (IL-2) production by T cells [10], 
their proteasomal degradation induced by lenalidomide 
releases this inhibition and enhances T cell stimulation [9].
The killing of MMCs by lenalidomide is partially 
explained by the down-regulation of interferon 
regulatory factor 4 (IRF4), a transcription factor essential 
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for MMC survival [11, 12]. Recent works have shown 
that lenalidomide-induced IRF4 inhibition in MMCs 
occurs downstream of Ikaros/Aiolos reduction and 
suggest that IRF4 is a transcriptional target of Ikaros 
and/or Aiolos [7, 8, 13].
IMiD effects on PCs, the healthy counterpart of 
MMCs, are unknown. Aiolos has a critical role in the 
generation of bone marrow (BM) PCs in mice [14], 
and IMiDs could target human PC generation as well. 
Indeed, Aiolos-deficient mice are unable to generate 
high affinity antibodies upon T cell-dependent antigen 
vaccination, whereas their ability to form germinal center 
and memory B cells (MBCs) is unaffected [14]. The 
generation of BM PCs requires the sequential activation, 
differentiation and trafficking of B cells, plasmablasts 
and PCs in different compartments (lymph nodes, lymph, 
blood and BM) [15]. Circulating PBs are short-lived cells 
that must find a niche in the BM or mucosal tissues to 
provide them with the factors required to survive and to 
fully differentiate into BM PCs (about 0.25% of human 
BM cells) [15].
We and others have shown that PC generation 
can be modeled using multi-step culture systems 
where various combinations of activation molecules 
and cytokines are successively used to reproduce 
the sequential cell differentiation occurring in the 
different organs/tissues in vivo [16–20]. In these culture 
models, MBCs differentiate into CD20low/-CD38- pre-
plasmablasts (prePBs), CD20-CD38+CD138- PBs, 
CD20-CD38+CD138+ early PCs and long-lived PCs 
(LLPCs), which may survive and produce continuously 
high amounts of immunoglobulins (Igs) for months in 
vitro [21, 22]. The phenotype of in vitro-generated PBs 
and early PCs is similar to the phenotype of the few 
PBs detected in the peripheral blood (2 PBs/mm3) [19, 
23]. Moreover, the molecular events occurring during 
differentiation of B cells into PCs are recapitulated in 
these in vitro differentiation models. In prePBs, which 
secrete Igs weakly, PC transcription factors (BLIMP1 
and XBP1, mainly unspliced XBP1 mRNA) start to 
be expressed, while BCL6, PAX5 and other B cell 
transcription factors are progressively down-regulated. 
This change is more pronounced in early PCs (high 
Ig secretion) in which expression of PAX5 and BCL6 
is inhibited and the ratio of spliced to unspliced XBP1 
mRNA is increased [20].
Using this model, here we show that lenalidomide 
mainly targets the generation of highly proliferating 
prePBs, poorly proliferating early PCs and non-
proliferating LLPCs. Conversely, lenalidomide does not 
affect much the generation of proliferating PBs and does 
not alter the long-term survival of LLPCs, once generated. 
Despite the different sensitivity of PBs and early PCs 
to lenalidomide, the expression of lkaros and Aiolos is 
comparably reduced in both cell types upon incubation 
with this drug.
RESULTS
Sequential generation of long-lived plasma cells
To investigate the effect of lenalidomide on 
the generation of human LLPCs from MBCs, we 
used an in vitro model that mimics the various steps 
associated with this process in lymph nodes, blood and 
BM [19, 20, 22]. In step 1 (four days of culture with 
soluble CD40 ligand (CD40L), phosphorothioate CpG 
oligodeoxynucleotides (ODN), IL-2, IL-10 and IL-15), 
purified MBCs are activated and induced to differentiate 
into highly proliferating CD20low/-CD38- prePBs that 
start to differentiate into CD20-CD38+ PBs [20]. In step 
2, cells are cultured with IL-2, IL-10, IL-15 and IL-6, 
but without CD40L and ODN for three days (day 4 to 7) 
to promote differentiation into CD20-CD38+ PBs, which 
start to differentiate into poorly proliferating CD20-
CD38+CD138+ early PCs. In step 3, cells are cultured 
in the presence of IL-6, IL-15 and interferon-alpha to 
complete PB maturation into CD20-CD38+CD138+ early 
PCs. In step 4 (addition of IL-6, APRIL and stromal 
cell-conditioned medium), early PCs finally differentiate 
into CD20-CD38+CD138+ non-cycling LLPCs and in 
step 5, newly generated LLPCs are allowed to survive 
and produce Igs continuously for months. Figure 1A-1B 
shows a schema of the culture model with the times of 
lenalidomide addition.
Lenalidomide impairs the generation of 
proliferating pre-plasmablasts mainly by 
reducing the number of cell divisions
Addition of lenalidomide at the start of step 1 (day 
0 to 4; differentiation of MBCs mainly into CD20low/-
CD38- prePBs and then CD20-CD38+ PBs) reduced 
the cell count (IC50 = 0.75 μM, a concentration in the 
range of those observed in patients treated with 25 mg 
lenalidomide daily) (Figure 2A) [24], but marginally 
reduced cell viability (Figure 2B). This effect was 
observed in the final day of step 1, when cells started 
cycling (Figure 2C). Moreover, 0.75 µM lenalidomide 
inhibited the generation of CD20low/-CD38- prePBs 
by 58% compared to control cells (DMSO alone) 
(Figures 3A-3C). As cell viability was not affected, 
we investigated whether this inhibition was due to a 
reduction in the number of cycling and dividing cells. 
Indeed, the percentage of prePBs in S phase was 
decreased by 42% (45% of control cells versus 26% 
of cells incubated with 0.75 µM lenalidomide were in 
S phase) and the fraction of prePBs in G1 phase was 
increased by 34% (Supplementary Figure S1A). The 
mean number of cell divisions in prePBs was decreased 
by 17% (from 3.5 to 2.9 divisions) (Figure 3D and Table 
1). Detailed flow cytometry data of a representative 
experiment are shown in Supplementary Figure S2.
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Concomitantly with the generation of CD20low/-
CD38- prePBs, MBC activation resulted also in the 
production of activated CD20highCD38- B cells (17% of all 
day-4 cells) (Figures 3A-3C) as previously reported [20]. 
In the presence of 0.75 µM lenalidomide, the count of 
activated B cells was reduced by 51% compared to control 
cells (Figure 3C), as a result of the decrease in the fraction 
of cycling and dividing cells (Supplementary Figure S1B, 
Figure 3D and Table 1).
During step 1, some CD20low/-CD38- prePBs 
further differentiated into CD20-CD38+ PBs (Figures 
3A-3C). Since exposure to lenalidomide hindered the 
generation of prePBs and because PBs originate from 
this compartment,[20] PB count was also reduced in the 
treated cultures, compared with control (DMSO), at the 
end of step 1 (Figure 3C). However, the effect on PB count 
was about 2-fold lower than that on prePBs (34% versus 
58% reduction, P ≤ .05). Similarly, the effect of 0.75 µM 
lenalidomide on the cell cycle was less strong in PBs 
than in prePBs: the PB fraction in S phase was reduced 
only by 17% compared with 42% in prePBs (P ≤ .05, 
Supplementary Figure 1A and 1C). Thus, lenalidomide 
mainly impairs prePB generation.
Lenalidomide did not significantly affect the 
frequency of IgM-, IgA- or IgG-producing activated 
B cells, prePBs and PBs (Supplementary Figure S3) or 
the expression of various membrane markers (CD19, 
CD24, CD30, CD45, CD126 and FCRL4). It only 
slightly increased CD31 expression in PBs (P = .009) 
(Supplementary Figure S4).
Lenalidomide strongly inhibits the generation 
of CD138+ early plasma cells, but not of 
plasmablasts
In step 2 (day 4 to 7), CD20low/-CD38- prePBs 
differentiate into CD20-CD38+ PBs and then into CD20-
CD38+CD138+ early PCs. Addition of lenalidomide 
at the beginning of this step led to a concentration-
dependent reduction of early PC number at day 7 (50% 
Figure 1: In vitro model to investigate lenalidomide effect during memory B cell differentiation into long-lived plasma 
cells. A. Using a five-step culture system, human memory B cells are induced to differentiate into long-lived plasma cells from day 0 to 
day 30. They can then be maintained in culture up to day 180. The cytokines used and the phenotype of the obtained cell populations at 
each step are indicated. B. The effect of lenalidomide on the different populations (from memory B cells to plasma cells) is investigated at 
the end of each differentiation step. Vertical arrows indicate when lenalidomide is added.
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reduction with 0.15 µM lenalidomide) (Figure 4A-4B). 
Conversely, PB number was considerably less affected. It 
was significantly reduced (by 17%) only upon incubation 
with 1.33 μM lenalidomide, a concentration which is 
about 10-fold higher than the early PC 50% inhibitory 
concentration (IC50) (P = .02, Figure 4C). Lenalidomide 
did not inhibit PB cell cycle at day 7 (Supplementary 
Figure S1D). The count and viability of all cells present in 
the cultures at day 7 were decreased, respectively, by 21% 
and 16% upon incubation with 0.15 µM lenalidomide and 
increasing lenalidomide concentrations had a stronger 
effect (Figures 4D-4E).
During step 3 (day 7 to day 10; maturation into 
CD20-CD38+CD138+ early PCs), incubation with 
lenalidomide reduced the generation of day-10 early PCs, 
with an IC50 of 0.76 µM (Figure 5A-5B). Conversely, 
it affected PB count only when used at a concentration 
higher than 4 µM (Figure 5C). The cell count and viability 
of all cells present in the culture at day 10 were decreased, 
respectively, by 27% and 28% with 0.76 µM lenalidomide 
and by 40% and 45% when lenalidomide concentration 
reached 10 µM (Figure 5D-5E). Thus, lenalidomide 
strongly inhibits the generation of CD138+ early PCs, but 
not of PBs in steps 2 and 3.
Figure 2: Effect of lenalidomide on cell growth in the first four days of in vitro memory B cell differentiation into 
plasma cells. 1.5 x 105 MBCs were activated with ODN and CD40L and cultured for four days with IL-2, IL-10, IL-15 and in the presence 
of increasing concentrations of lenalidomide or the largest DMSO concentration used to dilute lenalidomide (DMSO; control). A. Counts 
of cells recovered at the end of the four days of culture. B. Cell viability was assayed by trypan blue exclusion at day 4. C. Kinetics of cell 
amplification from D0 to D4, cells were cultured in the presence of control DMSO, 0.15 µM or 0.75 µM lenalidomide. Results are the mean 
value ± SD of four experiments. * P ≤ .05, compared with the control DMSO group using a paired t-test.
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Lenalidomide reduces the generation of long-
lived plasma cells, but does not affect their 
survival once established
In step 4 (generation of CD20-CD38+CD138+ 
LLPCs), purified day-10 early PCs were cultured with IL-
6, APRIL and stromal cell-conditioned medium (SC-CM) 
for 20 days. Lenalidomide was added at the beginning and 
then every week to ensure a continuous drug exposure 
according to the manufacturer’s recommendations. In 
this step, cells poorly cycle and only 20% survive and 
differentiate into LLPCs [22]. Lenalidomide reduced the 
number of LLPCs at day 30 with an IC50 below 1 µM 
(Figure 6A). During step 5, newly generated LLPCs may 
survive for months, if fresh IL-6, APRIL and SC-CM are 
added every week [22]. Incubation of LLPCs harvested 
Figure 3: Lenalidomide reduces the generation of pre-plasmablasts in the first step of the B cell to plasma cell 
differentiation model. MBCs were activated with ODN and CD40L and cultured for four days with IL-2, IL-10, IL-15 and in the 
presence of increasing concentrations of lenalidomide or the largest DMSO concentration used to dilute lenalidomide (DMSO; control). 
The percentage and count of activated B cells (CD20highCD38-), prePBs (CD20low/-CD38-) and PBs (CD20-CD38+) were determined by 
FACS analysis at day 4. A. Dot plot of CD20 and CD38 expression in day-4 cells (one representative experiment out of seven). The 
numbers in the panels (gates) are the percentages of gated day-4 cells. Dashed lines indicated the limit of CD20 positivity determined 
using an isotype-matched control antibody. B and C. Mean percentage and count ± SD (seven separate experiments) of activated B cells, 
prePBs and PBs at day 4 following incubation with 0.15 µM or 0.75 µM lenalidomide. D. Mean number (three separate experiments) of cell 
divisions to generate activated B cells, prePBs, or PBs at day 4. Cells were labeled with CFSE at the start of the culture and the decrease in 
CFSE staining due to cell division was evaluated at day 4. * P ≤ .05, compared with the control DMSO group using a paired t-test.
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Table 1: Lenalidomide reduces the number of cell division at day 4





Total cells 3.2 ± 0.4 2.9 ± 0.5* 2.5 ± 0.7*
Activated B cells
(CD20highCD38-) 2.0 ± 0.4 1.5 ± 0.5
* 1.4 ± 0.5*
PrePBs
(CD20low/-CD38-) 3.5 ± 0.2 3.2 ± 0.2
* 2.9 ± 0.4*
PBs
(CD20-CD38+) 4.1 ± 0.3 4.0 ± 0.4 3.5 ± 0.4
Mean number of cell divisions ± SD (three separate experiments) to generate activated B cells, prePBs, or PBs at day 
4. Cells were labeled with CFSE at the start of the culture and the decrease in CFSE staining due to cell division was 
evaluated at day 4. * P ≤ .05 compared with the control group (DMSO) using a paired t-test.
Figure 4: Lenalidomide preferentially targets the generation of CD138+ early plasma cells and poorly affects that 
of plasmablasts in the second step of in vitro B cell differentiation into plasma cells. Cells harvested at the end of step 
1 (day-4 cells: mainly prePBs and PBs) were cultured with IL-2, IL-6, IL-10 and IL-15 in the presence of graded concentrations of 
lenalidomide or the largest DMSO concentration used to dilute lenalidomide (DMSO) for three days. The percentage and counts of PBs 
(CD20-CD38+CD138-) and early PCs (CD20-CD38+CD138+) were determined by FACS analysis at day 7. A. Dot plot of CD38 and CD138 
expression in day-7 cells (one representative experiment out of four). The numbers in the panels (gates) are the percentage of gated day-7 
cells. B and C. Mean count ± SD of early PCs and PBs at day 7 in the presence of increasing lenalidomide concentrations from day 4 to 
day 7 (four separate experiments). D and E. Mean count and viability ± SD of all day-7 cells in the presence of increasing lenalidomide 
concentrations from day 4 to day 7 (four separate experiments). * P ≤ .05, compared with the DMSO control group using a paired t-test.
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at day 30 with up to 10 µM lenalidomide for four (day 
34) or 11 days (day 41) did not significantly affect the 
survival of established LLPCs (Figure 6B). Lenalidomide 
also did not modify their ability to produce IgG and IgA 
(Supplementary Figure S5A- S5B). These LLPCs did 
not cycle without or with lenalidomide (Supplementary 
Figure S1E).
Ikaros and Aiolos are expressed in plasmablasts 
and early plasma cells and their expression is 
inhibited by lenalidomide
Ikaros and Aiolos expression levels in FACS-
sorted day-7 PBs, day-10 PBs and day-10 early PCs 
were reduced by 70-80% and 50-65%, respectively, 
Figure 5: Lenalidomide preferentially targets the generation of CD138+ early plasma cells and poorly affects 
plasmablasts in the third step of the B cell to plasma cell differentiation model. Cells harvested at the end of step 2 (day-7 cells, 
mainly PBs and early PCs) were cultured with IL-6, IL-15 and IFN- α for three days (step 3) in the presence of increasing concentrations of 
lenalidomide or the largest DMSO concentration used to dilute lenalidomide (DMSO; control). The percentage and counts of PBs (CD20-
CD38+CD138-) and early PCs (CD20-CD38+CD138+) were determined by FACS analysis at day 10. A. Dot plot of CD38 and CD138 
expression in day-10 cells (one representative experiment out of four). The numbers in the panels (gates) are the percentage of gated day-10 
cells. B and C. Mean count ± SD of early PCs or PBs at day 10 in the presence of increasing lenalidomide concentrations from day 7 to 
day 10 (four separate experiments). D and E. Mean count and viability ± SD of all day-10 cells in the presence of increasing lenalidomide 
concentrations from day 7 to day 10 (four separate experiments). * P ≤ .05, compared with the DMSO control group using a paired t-test.
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following incubation with lenalidomide (Figure 7A-
7D). Similar results were obtained in OMP2 myeloma 
cells (positive control) treated with lenalidomide 
(Figure 7A-7D). This indicates that the differential 
sensitivity of PBs and early PCs to lenalidomide is not 
due to a difference in expression/targeting of Ikaros 
and Aiolos. The different sensitivity to lenalidomide 
could not be explained by differences in CRBN gene 
expression because it was similarly expressed in the 
various cell populations generated during plasma cell 
differentiation (Supplementary Figure S6A). CRBN 
protein expression levels, normalized to actin content, 
also were comparable in PBs and early PCs, despite the 
10-fold higher sensitivity to lenalidomide of early PCs 
(Supplementary Figure S6B).
Lenalidomide reduces IRF4 expression in 
activated B cell to plasma cell populations
Lenalidomide reduced in a dose-dependent 
manner IRF4 expression (measured by flow cytometry) 
in OPM2 myeloma cells (60% reduction with 10 µg/ml 
Figure 6: Lenalidomide targets the generation, but not the survival of long-lived plasma cells. Early PCs generated at the 
end of step 3 (day-10 cells) were FACS-sorted based on CD138 expression and lack of CD20 expression (> 95% purity). A. Purified early 
PCs were cultured for 4, 10 or 20 days with IL-6, APRIL and stromal cell-conditioned medium (SC-CM) in the presence of increasing 
concentrations of lenalidomide or the largest DMSO concentration used to dilute lenalidomide (DMSO). Fresh lenalidomide, DMSO, 
culture medium, cytokines and SC-CM were refreshed every week by replacing half of the culture medium. Counts of metabolically active 
LLPCs were assayed at day 14, 20 and 30 using a Cell Titer Glo Assay. Data are expressed as the percentage (mean ± SD; n= three separate 
experiments) of the values obtained in controls (DMSO). B. 30-day LLPCs were incubated with increasing lenalidomide concentrations 
or the largest DMSO concentration used to dilute lenalidomide (DMSO) for 4 or 11 days. Fresh lenalidomide, control DMSO, culture 
medium, cytokines and SC-CM were refreshed every week, by replacing half of the culture medium. Counts of metabolically active LLPCs 
were assayed at day 34 and 41. Data are expressed as the percentage (mean ± SD; n= three separate experiments) of the values obtained in 
controls (DMSO). * P ≤ .05, compared with the control group (DMSO) using a paired t-test.
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lenalidomide, Figure 7E and Supplementary Figure S7). 
It also significantly (P ≤ .05) reduced IRF4 expression in 
a dose-dependent manner in activated B cells, prePBs, 
PBs and early PCs (Figure 7E and Supplementary Figure 
S7). This effect was already significant with 0.1 µM 
lenalidomide and with 10 µM lenalidomide, IRF4 decrease 
varied from 23% in PBs to 36% in activated BCs. IRF4 
reduction was comparable in PBs and early PCs with 1 
µM and 10 µM lenalidomide (23% and 24% respectively). 
Interestingly, IRF4 downregulation was more pronounced 
in early PCs than in PBs with low doses of lenalidomide 
(0.01 µM and 0.1 µM) (Figure 7E).
Figure 7: Ikaros, Aiolos and IRF4 are expressed in plasmablasts and early plasma cells and their expression is reduced 
by lenalidomide. PBs generated at step 2 (day-7 cells), PBs and early PCs generated at step 3 (day-10 cells) were incubated with 10 µM 
lenalidomide or control DMSO for the last 24 hours of culture and were FACS-sorted based on CD38 expression and lack of CD20 and 
CD138 expression19 (PBs, ≥ 95% purity), and on CD138 and CD38 expression and lack of CD20 expression (early PCs ≥ 95% purity). 
OPM2 myeloma cells were incubated with 10 µM lenalidomide or control DMSO for 24 hours. Cell lysates were separated by SDS-PAGE 
and Ikaros and Aiolos expression assessed by immunoblotting. β actin expression was used as loading control. Representative western blot 
of Ikaros A. and Aiolos C. expression (three separate experiments). Data in B and D. are the mean Ikaros and Aiolos expression in the three 
experiments, quantified by densitometry analysis and normalized to actin levels. * P ≤ .05, compared with the control group (DMSO) using 
a paired t-test. E. Lenalidomide reduces IRF4 expression. Cells were cultured in the presence of increasing concentrations of lenalidomide 
or DMSO (control). Lenalidomide was added for three or four days at the beginning of each step, as indicated in Supplementary Figure 
S1B. The human myeloma cell line OPM2 was cultured for 3 days. At the end of each step, IRF4 expression was measured by flow 
cytometry analysis. Data are expressed as the percentage (mean ± SD; 3 separate experiments) of the IRF4 staining index values obtained 
in the control group (DMSO).
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Treatment with lenalidomide does not affect 
the count of normal bone marrow plasma cells 
in vivo
Twelve allografted patients with MM received 25 
mg lenalidomide daily for 3 to 18 months following the 
detection of residual MMCs. Patients with increasing 
counts of malignant PCs during lenalidomide treatment 
were not considered in order to eliminate a possible 
competition between malignant and normal PCs for the 
same niche. BM MMCs and normal PCs were monitored 
regularly during the treatment. Although the number of 
BM PCs in each patient fluctuated over time, possibly 
due to BM sample variation, the mean count during the 
lenalidomide treatment did not differ from that before 
treatment (Figure 8).
DISCUSSION
The main results of this study can be summarized 
in four points:
Lenalidomide reduces the generation of highly 
proliferating pre-plasmablasts
We and others have shown that the differentiation 
of MBCs into prePBs and then PBs is a process requiring 
several cell divisions [17]. In agreement, here we 
found that prePBs are actively cycling (45% of prePBs 
in S phase). Lenalidomide impaired prePB formation 
by reducing the percentage of prePBs in S phase and 
increasing the fraction in G1 without affecting their 
viability. This is in line with the ability of lenalidomide 
to induce the cell cycle inhibitors p21WAF1 and p27KIP1 in 
tumor cell lines, particularly by promoting demethylation 
of the p21WAF1 gene promoter [25].
Lenalidomide poorly affects PB formation but 
dramatically inhibits the generation of early PCs
Lenalidomide reduced the early PC count with 
an estimated 50% inhibitory concentration of 0.76 µM, 
similar to the concentration that inhibits prePB formation. 
Conversely, lenalidomide began to affect PB generation 
only at 10-fold higher concentrations and did not impair 
their cell cycle. Early PCs are more differentiated than 
PBs. They are poorly cycling cells that express more 
cytoplasmic Igs, lack membrane Igs (PBs still express 
a low amount of membrane Igs) and strongly express 
CD27 and CD138 (syndecan-1) [19]. The primary targets 
of lenalidomide are the Ikaros and Aiolos transcription 
factors [7-9, 13]. However, the 10-fold difference in 
sensitivity of proliferating PBs and poorly proliferating 
early PCs to lenalidomide is not explained by differences 
Figure 8: Lenalidomide treatment does not affect the counts of normal bone marrow plasma cells in allografted patients 
with multiple myeloma. Twelve patients with MM who received an allogeneic hematopoietic stem cell transplant were treated with 25 
mg lenalidomide daily for 3-18 months. Tumor and normal PCs were regularly monitored. All the patients had stable counts of tumor PCs 
during lenalidomide treatment. Normal PCs were identified as CD38high, CD19+, CD27+, CD56-, CD117-, CD200- and cytoplasmic Kappa or 
Lambda Ig light chain+ cells using multicolor cytometry. Data are expressed as the normal PC counts/106 leukocytes in the BM of each patient, 
harvested before and at different times during lenalidomide treatment. The black bold line represents the mean value of the patients’ PC counts.
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in Ikaros and Aiolos expressions in these two cell types. 
Alternatively, lenalidomide could degrade more efficiently 
Ikaros or Aiolos in early PCs than in PBs. This was not 
the case when these cells were incubated with 10 µM 
lenalidomide (60% to 80% reduction in both cell types). 
However, we cannot exclude that these transcription 
factors might be degraded more efficiently in early PCs 
than in PBs when lower lenalidomide concentrations are 
used. We could not fully investigate this point because of 
the difficulty in obtaining enough cells to assess protein 
expression by western blotting at different time points and 
upon incubation with various lenalidomide concentrations. 
Moreover, the anti-Ikaros and-Aiolos antibodies, which 
are reported to be efficient for protein quantification by 
FACS, worked with myeloma cells in our hands, but not 
with the in vitro generated cell populations, probably due 
to the weak expression of these proteins in these cells. 
Nevertheless, this point should be further investigated 
when more efficient antibodies become available.
In myeloma cells, IRF4 is a major transcription 
factor for initiating plasma cell differentiation and Ikaros 
and Aiolos control IRF4 gene expression [7, 8, 13]. 
Lenalidomide also negatively modulates IRF4 expression 
as a consequence of the degradation of Ikaros and Aiolos 
[7, 8, 13]. In agreement, we found that lenalidomide 
degrades in a dose-dependent manner IRF4 in activated 
B cells, prePBs, PBs and early PCs. IRF4 degradation is 
much more pronounced in early PCs than in PBs treated 
with low doses of lenalidomide (i.e. 0,01 µM and 0,1 µM) 
but is comparable with higher doses (1 and 10 µM). At 
day-10 of culture, there is a significant decrease of cell 
viability affecting mainly early PCs [19]. IRF4 expression 
is critical for PC survival [11, 12], so we can hypothesize 
that early PCs surviving with high doses of lenalidomide 
are those selected according to high IRF4 expression. 
This could explain the absence of significant difference 
in IRF4 expression between early PC and PB at 10 µM 
lenalidomide concentration. Lenalidomide-induced IRF4 
degradation in normal PBs and PCs is less pronounced than 
in OPM2 myeloma cells, possibly because IRF4 expression 
is deregulated in myeloma cells through continuous 
triggering by aberrant MYC expression [11, 12].
Lenalidomide efficiently targets the generation 
of long-lived PCs from early PCs in vitro
Lenalidomide inhibits the generation of LLPCs 
starting from purified early PCs with an IC50 lower than 1 
µM, a concentration in the range of those inhibiting prePB 
or early PC generation. The ability to generate LLPCs in 
vitro was recently documented by Cocco et al. and by our 
group [21, 22]. Our results fit well with the phenotype of 
Aiolos-deficient mice [14]. Indeed, they cannot generate 
PCs that produce Igs for a prolonged time [14]. As 
lenalidomide specifically targets Ikaros and Aiolos, these 
in vivo [14] and in vitro (our study) findings suggest that 
Aiolos and/or Ikaros are critical for LLPC generation from 
early PCs. In the current study, we could not determine 
Ikaros and Aiolos expression in LLPCs because of the 
too limited number of available LLPCs for western blot 
analysis. Indeed, only a few LLPCs can be generated 
due to the high cell loss occurring during the early PC 
and LLPC generation steps (80% of differentiating cells 
will die) [19, 22]. Moreover, although Ikaros and Aiolos 
immunodetection by FACS was previously reported 
in myeloma cell lines [13], we did not obtain specific 
labeling in PBs or early PCs and therefore could not use 
this approach in LLPCs (results not shown).
Once LLPCs are generated, lenalidomide 
does not affect their long-term survival and Ig 
production
The in vitro generation of LLPCs from early PCs is 
a highly selective process, but once LLPCs are generated, 
they can efficiently survive for months in vitro [21, 22]. 
The current data indicate that Ikaros and Aiolos are not 
essential for LLPC survival in our in vitro differentiation 
system. Moreover, LLPC survival might not be affected 
by lenalidomide also in vivo. Indeed, in patients with 
MM who received a stem cell transplant, lenalidomide 
treatment for 3 to 18 months following detection of 
residual tumor cells did not affect the mean count of 
normal BM PCs, identified by flow cytometry. These 
data suggest that Ikaros and/or Aiolos are dispensable for 
the long-term survival of human LLPCs in vitro and in 
vivo. It should be interesting to investigate the changes 
in MBCs, prePBs, PBs and PCs in patients treated with 
lenalidomide.
In conclusion, this study shows that lenalidomide 
affects minimally the formation of human PBs, specifically 
targets the generation of prePBs from MBCs, of early PCs 
from PBs and of LLPCs from early PCs, and does not alter 
the survival of LLPCs once generated, in agreement with 
the lack of effect on normal BM PCs in patients treated 
with lenalidomide. As lenalidomide specifically targets 
Ikaros and Aiolos proteins, these data suggest a major role 
of these transcription factors in regulating the generation 
of early PCs and LLPCs in humans.
The specific targeting of plasma cell precursors 
by lenalidomide should prompt to investigate whether 
resistance of plasma cell tumors to lenalidomide 
is associated with the selection of plasmablast or 
mature plasma cell subclones. Multiple myeloma is a 
heterogeneous tumor the growth of which is supported by 
MM progenitors that differentiate into mature MMCs [26]. 
The phenotype of MM progenitors that generate tumors in 
immune-compromised mice is controversial, particularly 
their expression of CD138 [26, 27], the marker that 
discriminates early PCs (sensitive to lenalidomide) from 
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PBs (poorly sensitive) in the current report. A recent 
study has shown that the proteasome inhibitor bortezomib 
kills preferentially mature and plasmablastic MMCs 
and that bortezomib resistance is associated with the 
emergence of pre-plasmablastic MMCs [28] (Figure 9B). 
The current data suggest that the MMC phenotype in 
patients resistant to lenalidomide should be investigated 
to determine whether resistance is associated with the 
emergence of poorly proliferating long-lived plasma cells 
or of CD38+CD138- plasmablasts. In this case, the clinical 
benefit of lenalidomide and bortezomib association could 
be explained by the ability of this drug combination to kill 
pre-plasmablastic up to mature MMCs (Figure 9A-9B).
MATERIALS AND METHODS
Patients
This study was performed under approval of the 
Montpellier University Hospital Centre for Biological 
Resources (DC-2008-417). It included patients with multiple 
myeloma (MM) who received an allogeneic hematopoietic 
stem cell transplant after reduced intensity conditioning 
(fludarabine, intra-venous busulfan ± thymoglobulin) at 
the Department of Hematology, Montpellier University 
Hospital, France. They all signed a written informed 
consent according to the Helsinki Declaration and EBMT 
good clinical practice guidelines. Residual tumor disease 
was monitored using flow cytometry as indicated [29]. In 
the case of detection of ≥ 103 MMCs/L, patients (n=12) 
received 25 mg lenalidomide daily for 3-18 months with 
repeated monitoring of MMCs and normal PCs.
Reagents
Human recombinant interleukin (IL)-2 was 
purchased from R&D Systems (Minneapolis, MN, USA), 
interferon-alpha-2b (IFN- α, IntronA) from Merck Canada 
Inc. (Kirckland, Canada), IL-6, IL-10 and IL-15 from 
PeproTech (Rocky Hill, NJ, USA). Mouse monoclonal 
antibodies (mAbs) conjugated to allophycocyanin (APC), 
fluorescein isothiocyanate (FITC), peridinin chlorophyll 
protein-cyanin 5.5 (PerCP-Cy5.5), phycoerythrin (PE) or 
Pacific BlueTM (PB), and specific for human CD19 (clone 
HIB19), CD24 (clone ML5), CD27 (clone M-T271), CD30 
(clone BerH8), CD31 (clone WM59), CD38 (clone HIT2), 
CD56 (cloneB159), CD117 (clone 104D2), CD138 (clone 
RF8B2), IgG (clone G18-145), IgM (clone G20-127), 
lambda Ig light chain (clone JDC-12), kappa Ig light chain 
(clone TB28-2) and Ki67 (clone B56) were purchased from 
BD Biosciences (Le Pont De Claix, France); for CD200 
(clone OX104) from eBiosciences (San Diego, CA, USA); 
Figure 9: Effects of lenalidomide and proteasome inhibitor on the different stages of plasma cell differentiation.  
A. During plasma cell differentiation, lenalidomide inhibits the generation of prePBs, early PCs and LLPCs but has a moderate inhibitory 
effect on PBs and LLPCs once generated. B. As shown by Leung-Hagesteijn et al. in multiple myeloma [28], antibody-producing cells 
(APCs), PBs and PCs, are sensitive to proteasome inhibitor because of their high level of Ig synthesis. Proteasome inhibitor treatment 
induces endoplasmic reticulum-associated protein degradation (ERAD)-related stress.
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for CD20 (clone B9E9), CD45 (clone J33), CD126 (clone 
M91) and CD138 (clone B-A38) from Beckman Coulter 
(Fullerton, CA, USA); for IRF4 (clone IRF4.3E4) and 
FCRL4 (clone 580810) from BioLegend (San Diego, CA, 
USA); for IgA, IgM, and IgG (polyclonal goat Abs) from 
Southern Biotech (Birmingham, AL, USA).
Cell samples
Peripheral blood cells from healthy volunteers 
were purchased from the French Blood Center (Toulouse, 
France) and CD19+CD27+ MBCs were purified (≥ 95% 
purity) as described [19].
Cell cultures
MBCs were differentiated using a previously 
described five-step culture method [19, 20, 22]. All 
cultures were performed in Iscove modified Dulbecco 
medium (Invitrogen, Carlsbad, CA, USA) and 10% FCS. 
In step 1 (day 0 to day 4), 1.5 x 105/ml purified peripheral 
blood MBCs were seeded in 6-well culture plates and were 
activated for 4 days by 10 µg/ml of phosphorothioate CpG 
oligodeoxynucleotides (ODN) 2006 (Sigma-Aldrich, St 
Louis, MO, USA), 50 ng/ml histidine tagged soluble CD40 
ligand (CD40L) and 5 µg/ml of an anti-poly-histidine mAb 
(R&D Systems) in the presence of 20 U/ml IL-2, 50 ng/
ml IL-10 and10 ng/ml IL-15. In step 2 (day 4 to day 7), 
PBs were generated by removing ODN and CD40L and 
changing the cytokine cocktail (20 U/ml IL-2, 50 ng/ml IL-
6, 50 ng/ml IL-10 and 10 ng/ml IL-15). In step 3 (day 7 to 
day 10), PBs were differentiated into early PCs by adding 
50 ng/ml IL-6, 10 ng/ml IL-15 and 500 U/ml IFN- α. In 
step 4 (day 10 to day 30), early PCs were FACS sorted 
based on CD138 expression and lack of CD20 expression 
(> 95% purity) and differentiated into LLPCs by adding 
10 ng/ml IL-6, 100 ng/ml APRIL and 50% of stromal cell-
conditioned medium (SC-CM). Fresh culture medium, 
growth factors and SC-CM were added once per week and 
cultures were maintained until day 30. In step 5 (day 30 
to day 41), LLPCs were allowed to survive and produce 
continuously Igs in the presence of 10 ng/ml IL-6, 100 ng/
ml APRIL and 35% of SC-CM. The SC-CM was obtained 
by culturing confluent monolayers of Resto-6 SC cells for 
5 days. The culture supernatant was filtered with 0.2 μM 
filters and frozen. The Resto-6 cell line was obtained from 
lymph node-derived SCs, as previously described [30].
Various lenalidomide concentrations (Celgene 
Corporation, Summit, NJ, USA) were added at the start of 
each step and its effects evaluated by analyzing cell counts 
and phenotype at the end of each step. Supplementary 
Figure S1A- S1B shows a schema of the culture model 
with the times of lenalidomide addition.
Cell viability and cell growth assays
Cell concentration and viability were assessed 
with the trypan blue dye exclusion test. The number of 
metabolically active cells was determined by intracellular 
ATP quantitation with the Cell Titer Glo Luminescent 
Assay (Promega Corporation, Madison, WI, USA).
Cell cycle and immunophenotypic analysis
Cycling cells were identified by DAPI staining 
(Sigma-Aldrich) and cells in the S phase by incubation with 
bromodeoxyuridine (BrdU) for 1 hour followed by labeling 
with an anti-BrdU antibody (APC BrdU flow kit, BD 
Biosciences) according to the manufacturer’s instructions. 
For immunophenotypic analysis, cells were stained with 
a combination of 4 to 7 mAbs conjugated to different 
fluorochromes, as indicated [22]. The Cytofix/Cytoperm 
kit (BD Biosciences) was used for intracellular staining of 
IgM, IgA, IgG, IRF-4 or Ki67 antigen [19]. Flow cytometry 
analysis was performed with a FACSAria cytometer using 
FACSDiva 6.1 (Becton Dickinson, San Jose, CA, USA) and 
with a Cyan ADP cytometer driven by the Summit software 
(Beckman Coulter). The Kaluza software (Beckman 
Coulter) was used for data analysis. The fluorescence 
intensity of the cell populations was quantified using the 
staining index (SI) formula: [mean fluorescence intensity 
(MFI) obtained for a given mAb minus MFI obtained with 
a control mAb]/[2 times the standard deviation of the MFI 
obtained with the same control mAb] [19].
CFSE labeling
Cell division was assessed by CFSE labeling as 
previously described [31]. Briefly, purified MBCs were 
washed and re-suspended at a concentration of 106 cells/ml 
in PBS/0.1% BSA with 10 µM CFSE (Molecular Probes, 
Eugene, OR, USA), incubated at 37°C for 10 minutes and 
extensively washed before culture. At day 4 of culture, 
cells were washed and labeled with anti-PB-CD20 and 
anti-PerCP-Cy5.5-CD38 for flow cytometry analysis. Cell 
divisions were quantified using the ModFit LT software 
(Verity Software House, Topsham, ME, USA).
Western blot analysis
Cells were lysed in RIPA buffer (Cell Signaling 
Technology, Beverly, MA, USA) supplemented with 1 
mM phenylmethylsulfonyl fluoride immediately before 
use. Lysates were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (10% gels) and 
transferred to nitrocellulose membranes using an iBlot® 
Gel Transfer Device (InVitrogen). Non-specific membrane 
sites were blocked by incubation at room temperature 
in 140 mM NaCl, 3 mM KCl, 25 mM Tris-HCl (pH 
7.4), 0.1% Tween 20 (tris-buffered saline Tween-20), 
5% non-fat milk for 2 h, and then immunoblotted with 
rabbit polyclonal antibodies against Ikaros (Santa Cruz 
Biotechnology, Dallas, TX, USA), Aiolos (Cell Signaling 
Technology) or Cereblon (Sigma-Aldrich). As a control for 
protein loading, a mouse monoclonal anti-β-actin antibody 
(Sigma-Aldrich) was used. The primary antibodies 
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were visualized with peroxidase-conjugated goat anti-
rabbit (Sigma-Aldrich) or goat anti-mouse (Jackson 
ImmunoResearch, West grove, PA, USA) antibodies 
and an enhanced chemiluminescence detection system. 
Western blots were quantified by densitometry using 
the NIH ImageJ software (National Institutes of Health, 
Bethesda, MD, USA) and protein levels were normalized 
according to those of β-actin.
Analysis of Ig secretion
ELISA. Flow cytometry-sorted PCs (106 cells/
ml) were cultured for the indicated time with increasing 
lenalidomide concentrations or the largest DMSO 
concentration used to dilute lenalidomide (DMSO) and 
culture supernatants harvested. IgA and IgG concentrations 
were assessed by ELISA using human IgA and IgG ELISA 
kits from Bethyl Laboratories (Montgomery, TX, USA), 
according to the manufacturer's recommendations.
Detection of malignant and normal PCs in BM of 
patients with MM
Malignant and normal PCs were counted using 
the multi-parameter flow cytometry technique reported 
previously [29]. Briefly, erythrocyte-lysed BM samples 
were labeled with anti-CD19, CD20, CD38 and CD45 
monoclonal antibodies (mAbs) in association with anti-
CD138, CD27, CD56, CD117, CD200 mAbs or isotype 
controls. Cells were then fixed and permeabilized with 
the Cytofix/Cytoperm kit (BD Biosciences, Le Pont De 
Claix, France), and labeled with anti-Ig Kappa and anti-
Ig Lambda mAbs. Data were acquired with a Cyan flow 
cytometer, driven by the Summit 4.3 software (Beckman 
Coulter, Fullerton, CA, USA). B-lymphocytes were 
defined as [CD19+CD20+CD45+CD38-/+ and (Kappa+ or 
Lambda+)] cells and PCs as [CD38high and (Kappa+ or 
Lambda+) and (not B lymphocytes)] cells. MMCs were 
identified based on the monoclonal expression of Kappa or 
Lambda light chains together with the aberrant expression 
of one or several myeloma markers: CD20 and/or CD56 
and/or CD117 and/or CD200, lack of CD19, and lack/
weak CD27 and/or CD45 expression. [32–35] Healthy 
PCs were identified based on the polyclonal expression of 
Kappa or Lambda light chains together with the expression 
of CD19, CD27. The acquisition of at least 100 events 
was required to define MMCs or healthy PCs as detectable 
[36]. Data were analyzed with the FlowJo 9.1 software 
(Tree star, Ashland, OR).
Statistical analysis
Statistical comparisons were made with the non-
parametric Mann-Whitney test, unpaired or paired 
Student’s t-test using the SPSS software. P-values ≤ .05 
were considered as significant.
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